Generic Name and Formulations:
Fulvestrant 50mg/mL; soln for IM inj.
Indications for FASLODEX:
Hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Give by IM inj slowly (1–2 mins/injection). 500mg (as two 5mL injections, one in each buttock) on days 1, 15, 29, then once per month thereafter. Moderate hepatic impairment: 250mg (as one 5mL injection) on days 1, 15, 29, then once per month thereafter.
Bleeding diatheses, thrombocytopenia, or anticoagulant use. Moderate to severe hepatic impairment. Pregnancy (Cat.D; avoid); exclude pregnancy before starting. Nursing mothers: not recommended.
Estrogen receptor antagonist.
Inj site pain, GI upset, bone pain, arthralgia, headache, back pain, fatigue, pain in extremity, hot flash, anorexia, asthenia, musculoskeletal pain, cough, dyspnea, constipation; increased hepatic enzymes, hypersensitivity reactions.
Hepatic (CYP3A4); 99% protein bound.
Fecal (primarily), renal.
Prefilled syringe kit (2 x 5mL)—1
Sign Up for Free e-newsletters
- 2016 Recommended Immunization Schedule for Adults: What's Changed?
- 2016 Childhood and Adolescent Immunization Schedule Released
- First Sexually-Transmitted Zika Virus Case Confirmed in Texas
- Spiriva Respimat Gains Indication and New Dosage Strength
- To Rx or Not to Rx: Interventions to Improve Antibiotic Prescribing for Uncomplicated Acute RTI
- CDC Guidelines on Preventing Sexual Transmission of Zika Virus Issued
- CDC Updates Interim Zika Virus Guidelines for Pregnant Women and Women of Reproductive Age
- Daklinza Use Expanded to Cover Treatment in More HCV Patients
- Researchers Call for an Alternative Tdap Immunization Strategy for Adolescents
- FDA Announces Large Action Plan in Effort to Reverse the Opioid Epidemic